Home > About Us > Partnership Opportunities

Focus on pain management and enhanced drug delivery

Cytogel Pharma is currently considering partnering opportunities to license the proprietary Cyt-1010, the first in a new class of drugs, with a novel mechanism of action to enter the market, should it be approved. CYT-1010 has proven more potent than morphine with an improved side effect profile of less respiratory depression and less potential for causing addiction. CYT-1010 has received authorization to begin Phase 2 clinical studies and is preparing to begin these studies at this time. Cytogel is also considering additional relationships to expand the application of the company's hydrogel technology for enhanced drug delivery. These hydrogels may be made temperature- and/or pH-sensitive and may carry many times their weight in drug, potentially improving control of drug release and precision of delivery.

If you are interested in exploring a corporate partnership with Cytogel Pharma or would like additional information, please email:

C. Dean Maglaris, CEO

dmaglaris@cytogelpharma.com